Therefore, ovarian cancer patients with RUNX1 genetic alternation, which has poor prognosis and drug resistance, have been treated with the combination of clinical chemotherapy drugs (cisplatin, taxane, paclitaxel, and platinum agents) as a novel therapy strategy may generate a significant therapeutic outcome. The gene discussed is RUNX1; the disease is ovarian carcinoma.